EYE Stock Overview
Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services surgical devices for the treatment of glaucoma.
Nova Eye Medical Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.23|
|52 Week High||AU$0.42|
|52 Week Low||AU$0.18|
|1 Month Change||-10.00%|
|3 Month Change||18.42%|
|1 Year Change||-43.04%|
|3 Year Change||-60.53%|
|5 Year Change||-79.36%|
|Change since IPO||-62.05%|
Recent News & Updates
We Think Nova Eye Medical (ASX:EYE) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|EYE||AU Medical Equipment||AU Market|
Return vs Industry: EYE underperformed the Australian Medical Equipment industry which returned -22.7% over the past year.
Return vs Market: EYE underperformed the Australian Market which returned -11% over the past year.
|EYE Average Weekly Movement||11.2%|
|Medical Equipment Industry Average Movement||11.4%|
|Market Average Movement||9.6%|
|10% most volatile stocks in AU Market||16.9%|
|10% least volatile stocks in AU Market||4.3%|
Stable Share Price: EYE is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: EYE's weekly volatility (11%) has been stable over the past year.
About the Company
Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services surgical devices for the treatment of glaucoma. The company offers iTrack, a surgical system for the reduction in intraocular pressure (IOP) in adult patients with open-angle glaucoma; iTrack Advance, a natural ocular drainage system; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, the United States, Europe, the Asia Pacific, and internationally.
Nova Eye Medical Limited Fundamentals Summary
|EYE fundamental statistics|
Is EYE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EYE income statement (TTM)|
|Cost of Revenue||AU$2.29m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.051|
|Net Profit Margin||-56.03%|
How did EYE perform over the long term?See historical performance and comparison